Related Experiment Video
Updated: Aug 20, 2025
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Evaluation of oxindole derivatives as a potential anticancer agent against breast carcinoma cells: In vitro, in
Sachin Puri1, Iqrar Ahmad2, Harun Patel2
1Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai 400 056, India.
Abstract:
In this study we have performed the in vitro anticancer activity of spiro oxindole derivatives against MCF-7 (human Adreno carcinoma) and MDA-MB-231 (triple negative breast cancer) cell lines to propose a possible role of these derivatives in the treatment of cancer. Compound 6, which has an N-benzyl substitution with a chloro group on the indolin-2-one scaffold, had the most potent activity against MCF-7 (3.55 ± 0.49 μM) and MDA-MB-231 (4.40 ± 0.468 μM) of all the synthesized molecules. A normal mouse embryonic fibroblast (NIH/3 T3) cell line was used to test the cellular toxicity of these derivatives. The results showed that none of the compounds were cytotoxic to normal cells. In addition, pharmacokinetic (ADME) and toxicity study profiles were predicted in silico. All the synthesized derivatives (1 to 7) demonstrated the necessary physicochemical properties for bioavailability. Finally, in vitro results of promising compound 6 were validated using molecular docking and dynamic simulation studies, which revealed their binding affinities and conformational stability in the binding cavity. Thus, these derivatives may serve as lead structures for a new generation of anticancer agents.
Insights
Spiro oxindole derivatives show potent anticancer activity against breast cancer cell lines. Compound 6 demonstrated significant efficacy with no observed toxicity in normal cells, suggesting potential as novel anticancer agents.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cancer Research
Background:
- Cancer remains a leading cause of mortality worldwide, necessitating the development of novel therapeutic agents.
- Oxindole derivatives have emerged as a promising class of compounds with diverse biological activities, including anticancer properties.
Purpose of the Study:
- To synthesize and evaluate the in vitro anticancer activity of novel spiro oxindole derivatives against human breast cancer cell lines.
- To assess the cytotoxicity of these derivatives against normal cells.
- To predict pharmacokinetic and toxicity profiles and validate findings through computational studies.
Main Methods:
- Synthesis of spiro oxindole derivatives (compounds 1-7).
- In vitro anticancer assays using MCF-7 (human Adreno carcinoma) and MDA-MB-231 (triple negative breast cancer) cell lines.
- Cytotoxicity assessment using NIH/3T3 (normal mouse embryonic fibroblast) cell line.
- In silico prediction of pharmacokinetic (ADME) and toxicity profiles.
- Molecular docking and dynamic simulation studies for compound 6.
Main Results:
- Compound 6 exhibited the most potent in vitro anticancer activity against both MCF-7 (3.55 ± 0.49 μM) and MDA-MB-231 (4.40 ± 0.468 μM) cell lines.
- None of the synthesized spiro oxindole derivatives displayed significant cytotoxicity towards normal NIH/3T3 cells.
- All derivatives demonstrated favorable physicochemical properties for bioavailability, as predicted by in silico ADME studies.
- Molecular docking and dynamic simulations confirmed the binding affinity and conformational stability of compound 6 in the target binding cavity.
Conclusions:
- Spiro oxindole derivatives, particularly compound 6, show significant promise as anticancer agents with a favorable safety profile.
- These compounds possess suitable physicochemical properties for potential drug development.
- Further investigation and development of these derivatives could lead to a new generation of anticancer therapeutics.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
01:25Mutagenicity and Carcinogenicity